Events & Meetings / News - February 9, 2021
EUCOPE has the pleasure to participate to the 1st International Conference on Rare Diseases organised under the patronage of H.E. the President of the Hellenic Republic. The event, entitled “Building a Pathway from Diagnosis to Access” will take place virtually on the first and second… read more
EUCOPE Resources / Press Releases - January 7, 2021
EUCOPE, the European association for small to medium-sized companies active in pharmaceuticals and biotechnologies submitted its response to the Paediatric and Orphan Medicinal Products (OMPs) inception impact assessment. EUCOPE represents 130 companies, many focused on rare diseases, largely small to medium-sized, playing a key role… read more
News - January 1, 2021
Following a successful launch event, the TRANSFORM MEP Interest Group, a multi-stakeholder alliance of Members of European Parliament, patient groups, academia and industry, published two important documents to lay the foundations of an open discussion on key priorities for gene and cell therapies, namely a… read more
News - December 17, 2020
Published on 8 December, the European Medicines Agency (EMA) and Heads of Medicines Agency (HMA) Joint Strategy looks into six strategic focus areas: (1) Availability and accessibility of medicines, (2) Digital tools and digital transformation, (3) Innovation, (4) Antimicrobial resistance, (5) Supply chain challenges, and… read more
Events & Meetings / News - December 2, 2020
Aware of the complex European policy landscape that will keep policymakers busy in the months to come, EUCOPE wanted to discuss the European innovation leadership in the pharmaceutical sector and discover how the European Union and Member States can support pharmaceutical innovation in Europe. On… read more
EUCOPE Resources / News - December 1, 2020
EUCOPE’s approach to the EU environment for the development of OMPs On 11 August 2020, the European Commission published its evaluation on the legislation for medicines for rare diseases and for children. In November this was followed by an Inception Impact Assessment outlining policy options… read more
Events & Meetings / News - November 27, 2020
On 30/11, the European Medicines Agency (EMA) will organise a virtual event to encourage early and efficient interactions with the regulators by highlighting pre-marketing support in medicine development in rare diseases. The meeting will highlight and explain existing tools in the context of early product development strategy…. read more
EUCOPE Resources / News / Press Releases - November 25, 2020
EUCOPE, the European association for small to medium-sized companies active in pharmaceuticals and biotechnologies – many of which are researching and developing rare disease treatments – notes the publication of the European Commission Communication on the Pharmaceutical Strategy for Europe. EUCOPE calls for a comprehensive Pharmaceutical Strategy… read more
News - November 3, 2020
In light of the upcoming Pharmaceutical Strategy and ongoing Evaluation of the Orphan Medicinal Products (OMP) Regulation, the European Expert Group on Orphan Drug Incentives has been established to discuss and bring forward innovative proposals to stimulate innovation and foster research into new orphan drugs… read more
Events & Meetings / News - October 30, 2020
Pharmaceutical small to mid-sized companies and start-ups constitute a laboratory of innovation and should be nurtured through a forward-looking European incentives ecosystem that encourages the development of cutting-edge technologies. The upcoming EU health policy initiatives, including the Pharmaceutical Strategy for Europe and the impact assessment… read more
